Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
45 studies found for:    "Familial adenomatous polyposis"
Show Display Options
Rank Status Study
1 Recruiting Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP)
Condition: Familial Adenomatous Polyposis
Interventions: Procedure: Duodenoscopy and enteroscopy;   Genetic: Molecular analysis.
2 Completed
Has Results
Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)
Condition: Familial Adenomatous Polyposis
Interventions: Drug: Black raspberry (BRB) Slurry;   Drug: Black Raspberry (BRB) Suppositories;   Drug: Black Raspberry (BRB) Placebo Slurry
3 Withdrawn Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients
Condition: Familial Adenomatous Polyposis
Intervention: Drug: curcumin
4 Active, not recruiting Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Condition: Familial Adenomatous Polyposis
Interventions: Drug: Eflornithine plus Sulindac;   Drug: Eflornithine and Placebo;   Drug: Sulindac and Placebo
5 Recruiting Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
Condition: Familial Adenomatous Polyposis
Interventions: Drug: Calcumin (Curcumin);   Other: Risk Factor Questionnaire;   Other: Blood samples;   Other: Biopsies (Sigmoidoscopy);   Other: Biopsies (Upper endoscopy)
6 Unknown  Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis
Condition: FAP-Familial Adenomatous Polyposis
Intervention: Drug: Erythromycin
7 Not yet recruiting Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version
Condition: FAP-Familial Adenomatous Polyposis
Intervention: Drug: Erythromycin
8 Active, not recruiting Curcumin in Treating Patients With Familial Adenomatous Polyposis
Condition: Familial Adenomatous Polyposis
Interventions: Drug: Curcumin;   Other: Laboratory Biomarker Analysis;   Other: Placebo
9 Terminated
Has Results
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients
Condition: Familial Adenomatous Polyposis (FAP)
Interventions: Drug: Celecoxib;   Other: Routine Medical Care
10 Withdrawn A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
Condition: Familial Adenomatous Polyposis
Interventions: Drug: Eflornithine plus Sulindac;   Drug: Eflornithine plus Placebo;   Drug: Sulindac plus Placebo
11 Recruiting Non-Surgical Management of Attenuated and Deleterious (Classical) Familial Adenomatous Polyposis: A Long-term Surveillance Program
Conditions: Attenuated Familial Adenomatous Polyposis;   Deleterious Familial Adenomatous Polyposis
Intervention: Other: Chart Review
12 Unknown  The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study
Condition: Familial Adenomatous Polyposis
Intervention: Drug: metformin
13 Not yet recruiting Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
Conditions: Attenuated Familial Adenomatous Polyposis;   Familial Adenomatous Polyposis
Interventions: Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis
14 Active, not recruiting Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)
Conditions: Familial Adenomatous Polyposis;   Colorectal Cancer
Interventions: Behavioral: Web-Based Multimedia Intervention;   Behavioral: Questionnaire
15 Completed
Has Results
Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA
Conditions: Familial Adenomatous Polyposis Coli;   FAP
Interventions: Drug: Eicosapentanoic Acid (EPA);   Procedure: Endoscopy;   Procedure: Biopsies taken;   Drug: Placebo
16 Completed Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW
Condition: Adenomatous Polyposis Coli
Interventions: Drug: Bevacizumab-IRDye800CW;   Device: Near infrared fluorescence endoscopy platform
17 Terminated
Has Results
Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)
Condition: Adenomatous Polyposis Coli
Interventions: Drug: Celecoxib;   Drug: Placebo
18 Terminated A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)
Condition: Adenomatous Polyposis Coli
Interventions: Drug: MK0966; rofecoxib / Duration of Treatment: 24 weeks;   Drug: Comparator: placebo / Duration of Treatment: 24 weeks
19 Completed
Has Results
A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
Condition: Adenomatous Polyposis Coli
Interventions: Drug: Erlotinib;   Drug: Sulindac;   Drug: Placebo A;   Drug: Placebo B
20 Terminated
Has Results
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
Conditions: Colorectal Cancer;   Familial Adenomatous Polyposis
Interventions: Drug: Celecoxib;   Other: Placebo;   Drug: eflornithine;   Other: Laboratory biomarker analysis;   Other: Questionnaire administration

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.